canadian diabetes association clinical practice guidelines vascular protection in people with...
TRANSCRIPT
Canadian Diabetes Association Clinical Practice Guidelines
Vascular Protection in People with Diabetes Chapter 22
James A. Stone, David Fitchett, Steven Grover, Richard Lewanczuk, Peter Lin
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Vascular Protection Checklist 2013
A • A1C – optimal glycemic control (usually ≤7%)
B • BP – optimal blood pressure control (<130/80)
C • Cholesterol – LDL ≤2.0 mmol/L if decided to treat
D • Drugs to protect the heart (regardless of baseline BP or LDL)
A – ACEi or ARB │ S – Statin │ A – ASA if indicated
E • Exercise / Eating healthily – regular physical
activity, achieve and maintain healthy body weight
S • Smoking cessation
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
20-30 31-40 41-45 46-50 51-55 56-60 61-65 66-70 71-75 76-80 81-85
Absolute Risk of MI is Higher in Patients with DM
Age group
0.5
1.0
1.5
2.0
2.5
3.0
0No
. ev
ents
per
100
per
so
n-
year
s
Booth GL, et al. Lancet 2006;368:29-36.
All lines fitted according to a polynomial equation; R2= 0.99–1.00 for each
MI = myocardial infarction
Diabetes n = 379,003 No Diabetes n = 9,018,082 Database 1994-2000
No diabetesMen
Women
DiabetesMen
Women
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
MRFIT: Impact of Diabetes on Cardiovascular Mortality
Mor
talit
y pe
r 10
,000
140
120
100
80
60
40
20
0None
6
One only Two only All three
Number of risk factors*
1222
47
31
59
91
125Nondiabetes (n = 342,815)
Diabetes (n = 5,163)
*Risk factors analyzed: smoking, hypercholesterolemia and hypertension.
Stamler J, et al. Diabetes Care 1993; 16(2):434-44
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
T2DM for > 15 Years Duration Confers a Similar Risk of Fatal CHD as Prior CHD and No Diabetes
20 year follow-up of 121,046 women aged
30 to 55 years in Nurses’
Health Study
Hu F, et al. Arch Intern Med. 2001;161:1717-1723.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Multifaceted Management is Essential for T2DM
• Intensive multifaceted management in patients
with Type 2 diabetes lowers overall mortality
• Multifaceted treatment strategy includes:– Glucose, lipid, BP control
– Health behavior optimization
– Use of vascular protective medications
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
STENO-2
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Multifaceted Approach for CVD Prevention Among Patients with T2DM
Type 2 Diabetes +
Microalbuminuria
n = 160
Conventional ArmMD follows clinical practice guidelines
8-year follow-up composite outcome:CV death, MI, CABG, PCI, Stroke, Amputation, or PVD surgery
Gaede et al. NEJM. 2003: 348;383-393
Intensive ArmTherapies to achieve targets in glycemia, lipids, BP and microalbuminuria
Multidisciplinary care q3mo
ASA and ACE inhibitors
(independent of BP)
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Gaede et al. NEJM. 2003: 348;383-393
STENO-2: Intensive Group Achieved Targets
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Intensive Group had Improved CV Outcomes
12 24 36 48 60 72 84 960
10
20
30
40
50
60P = 0.007
Conventional therapy
Intensive therapy
Months of Follow-upRRR= relative risk reduction
53 % RRRAny CV event
NNT = 5
Gaede et al. NEJM. 2003: 348;383-393
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Gaede et al. NEJM. 2003: 348;383-393
STENO 2 – Microvascular Disease
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Use a Multifaceted Vascular Protection Strategy
BP <130/80
A1C ≤7%
Rx:StatinsACEi/ARB
Healthy Lifestyle/weight Smoking Cessation
PhysicalActivity
Vascular protective medications
• Statins
• ACE-inhibitors or Angiotensin receptor
blockers (ARB)
• ASA selective use
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
HPS: Statin Therapy Beneficial Among Patients with Diabetes
(10269) (10267)SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
999 1250(23.5%) (29.4%)Previous MI
460 591(18.9%) (24.2%)Other CHD (not MI)
No prior CHD
172 212(18.7%) (23.6%)CVD
327 420(24.7%) (30.5%)PVD
276 367(13.8%) (18.6%)Diabetes
24%reduction(P<0.00001)
2033 2585(19.8%) (25.2%)ALL PATIENTS
0.4 0.6 0.8 1.0 1.2 1.4
HPS Lancet 2002;360:7-22
HPS: Heart protection study
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
CARDS: Effect of Statin for PRIMARY Prevention in DM
• n = 2838• Age 40-75, no history of CVD• T2DM plus one or more:
– Retinopathy– Albuminuria– Hypertension– Smoking
• Intervention: Atorvastatin 10 mg vs. Placebo• Outcome: ACS, revascularization, stroke
Colhoun HM, et al. Lancet 2004;364:685.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
CARDS: Statins Reduced CVD in Patients with DM
Colhoun HM, et al. Lancet 2004;364:685.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
• ≥40 yrs old or • Macrovascular disease or• Microvascular disease or• DM >15 yrs duration and age >30 years or• Warrants therapy based on the 2012 Canadian
Cardiovascular Society lipid guidelines
Among women with childbearing potential, statins should only be used in the presence of proper preconception counseling &
reliable contraception. Stop statins prior to conception.
2013Who Should Receive Statins? (regardless of baseline LDL-C)
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
What if baseline LDL-C ≤2.0 mmol/L?
• Within CARDS and HPS, the subgroups that started
with lower baseline LDL-C still benefited to the same
degree as the whole population
• If the patient qualifies for statin therapy based on the
algorithm, use the statin regardless of the baseline
LDL-C and then target an LDL reduction of ≥50%
HPS Lancet 2002;360:7-22 Colhoun HM, et al. Lancet 2004;364:685.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Vascular protective medications
• Statins
• ACE-inhibitors or Angiotensin receptor
blockers (ARB)
• ASA selective use
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Association of SBP and CV Mortality in Men With T2DM
250
200
150
100
50
0<120 120-139 140-159 160-179 180-199
SBP (mmHg)
CV
mor
talit
y ra
teP
er 1
0,00
0 pe
rson
-yea
rs
No diabetesDiabetes
≥200
Stamler J, et al. Diabetes Care. 1993;16:434-444.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
UKPDS Study Group. BMJ 1998; 317:703-13.
50
40
30
20
10
0
Years from randomization
Pat
ient
s w
ith e
vent
s (%
)
0 1 2 3 4 5 6 7 8 9
Less tight control (mean BP 154/87 mmHg)
Tight control (mean BP 144/82 mmHg)
Tight BP control:24% reduction of events(95% CI 8-38)
Tight BP control:24% reduction of events(95% CI 8-38)
Hypertension in Diabetes UKPDS
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
P<0.005
MI,
str
oke,
CV
m
orta
lity/
1000
pt-
yDiabetes Subgroup
90 mm Hg (n=501) 85 mm Hg (n=501) 80 mm Hg (n=499)
Goal of therapy: target diastolic BP
24.4
18.8
11.9
30
25
20
15
10
5
0Hansson et al. Lancet. 1998;351:1755.
HOT: BP Control Reduces CV Events
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Micro-HOPE (ACEi): CV Benefits
RR = 0.67 (0.5-0.9) p = 0.0074
RR = 0.78 (0.64-0.94) p = 0.01
RR = 0.63 (0.49-0.79) p = 0.001
Stroke(NNT 53)
CV Death(NNT 29)
MI(NNT 37)
0 400 800 12001600
0
0.1
0.2Placebo
Ramipril 10 mg
Primary Outcome (NNT 22)
0 400 800 1200 16000
0.08
0.16 All Mortality(NNT 31)
RR = 0.76 (0.63-0.92) p = 0.004
0 1000 2000
0
0.06
0.12
0 1000 2000
0
0.04
0.08
0 1000 20000
0.08
0.16
Duration of follow-up (days)
Kap
lan
-Mei
er r
ates RR = 0.75 (0.64-0.88)
p = 0.0004
HOPE study investigators. Lancet. 2000;355:253-59.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
ONTARGET: ARB Therapy is as Effective as ACEi for CVD Prevention
ONTARGET study investigators. NEJM. 2008:358:1547-59.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Who Should Receive ACEi or ARB Therapy?(regardless of baseline blood pressure)
• ≥55 years of age or • Macrovascular disease or • Microvascular disease
At doses that have shown vascular protection [perindopril 8 mg daily (EUROPA), ramipril 10 mg daily
(HOPE), telmisartan 80 mg daily (ONTARGET)]
Among women with childbearing potential, ACEi or ARB should only be used in the presence of proper preconception
counseling & reliable contraception. Stop ACEi or ARB either prior to conception or immediately upon detection of pregnancy
2013
EUROPA Investigators, Lancet 2003;362(9386):782-788.HOPE study investigators. Lancet. 2000;355:253-59.
ONTARGET study investigators. NEJM. 2008:358:1547-59
Vascular protective medications
• Statins
• ACE-inhibitors or Angiotensin receptor
blockers (ARB)
• ASA selective use
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
What About ASA for 1 Prevention of CVD? ⁰
Included: Six studies, n = 10,117 participants
De Berardis G et al. BMJ 2009;339:b4531
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
JPAD = Japanese Primary Prevention of Atherosclerosis with Aspirin for DiabetesPOPADAD = Prevention of Progression of Arterial Disease and DiabetesPPP = Primary Prevention ProjectETDRS = Early Treatment Diabetic Retinopathy StudyPHS = Physicians’ Health StudyWHS = Women’s Health Study
De Beradis G, et al. BMJ 2009; 339:b4531.
ASA for 1⁰Prevention in DiabetesMeta analysis of 6 studies(n = 10,117)
No overall benefit for: • Major CV events • MI• Stroke• CV mortality• All-cause mortality
0.03 0.125 0.5 12
8Favors ASA Favors control/placebo
JPADPOPADADWHSPPPETDRSTotal
68/1262105/63858/51420/519
350/1856601/4789
86/1277108/63862/51322/512
379/1855657/4795
0.80 (0.59-1.09)0.97 (0.76-1.24)0.90 (0.63-1.29)0.90 (0.50-1.62)0.90 (0.78-1.04)0.90 (0.81-1.00)
Major CV events
No. of events/No. in group
ASA Control/placebo RR (95% CI) RR (95% CI)
JPADPOPADADWHSPPPETDRSPHSTotal
28/126290/63836/5145/519
241/185611/275
395/5064
14/127782/63824/51310/512
283/185526/258
439/5053
0.87 (0.40-1.87)1.10 (0.83-1.45)1.48 (0.88-2.49)0.49 (0.17-1.43)0.82 (0.69-0.98)0.40 (0.20-0.79)0.86 (0.61-1.21)
Myocardial infarction
JPADPOPADADWHSPPPETDRSTotal
12/126237/63815/5149/519
92/1856181/4789
32/127750/63831/51310/51278/1855
201/4795
0.89 (0.54-1.46)0.74 (0.49-1.12)0.46 (0.25-0.85)0.89 (0.36-2.17)1.17 (0.87-1.58)0.83 (0.60-1.14)
Stroke
JPADPOPADADPPPETDRSTotal
1/126243/63810/519
244/1856298/4275
10/127735/6388/512
275/1855328/4282
0.10 (0.01-0.79)1.23 (0.80-1.89)1.23 (0.49-3.10)0.87 (0.73-1.04)0.94 (0.72-1.23)
Death from CV causes
JPADPOPADADPPPETDRSTotal
34/126294/63825/519
340/1856493/4275
38/1277101/63820/512
366/1855525/4282
0.90 (0.57-1.14)0.93 (0.72-1.21)1.23 (0.69-2.19)0.91 (0.78-1.06)0.93 (0.82-1.05)
All-cause mortality
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Insufficient evidence to support use of ASA for primary prevention
Risk of bleeding CVD protection
2013
ASA Not Routinely Recommended for 1 ⁰Prevention for CVD Among Patients with DM
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
• Do your part
• Protect their heart
Multifaceted approach + Individualize therapy
Don`t Forget To…………..
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Vascular Protection Checklist 2013
A • A1C – optimal glycemic control (usually ≤7%)
B • BP – optimal blood pressure control (<130/80)
C • Cholesterol – LDL ≤2.0 mmol/L if decided to treat
D • Drugs to protect the heart (regardless of baseline BP or LDL)
A – ACEi or ARB │ S – Statin │ A – ASA if indicated
E • Exercise / Eating healthily – regular physical
activity, achieve and maintain healthy body weight
S • Smoking cessation
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.ca
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
1. All individuals with diabetes (type 1 or type 2) should follow a comprehensive, multifaceted approach to reduce cardiovascular risk including:– Achievement and maintenance of healthy body weight– Healthy diet– Regular physical activity– Smoking cessation– Optimal glycemic control (usually A1C <7%)– Optimal blood pressure control (<130/80 mmHg)– Additional vascular protective medications in the majority
of adult patients
[Grade D, consensus for T1DM, children/adolescents; Grade A, Level 1 for T2DM]
Recommendation 1
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 2
2. Statin therapy should be used to reduce CV risk in
adults with type 1 or type 2 diabetes with any of the
following features:– Clinical macrovascular disease [Grade A, Level 1]
– Age ≥40 years [Grade A, Level 1 T2DM; Grade D Consensus T1DM]
– Age <40 and one of the following:
• Diabetes duration > 15 years and age >30 yrs
• Microvascular complication
• Warrants therapy for other reasons based on the 2012
CCS guidelines for the management of dyslipidemia [Grade D, consensus]
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 3
3. ACE inhibitor or ARB, at doses that have
demonstrated vascular protection, should be used
to reduce CV risk in adults with type 1 or type 2
diabetes with any of the following: – Clinical macrovascular disease [Grade A, Level 1]
– Age ≥55 years [Grade A, Level 1 for those with an additional risk factor
or end organ damage; Grade D, consensus for all others]
– Age <55 years and microvascular complications [Grade
D, consensus]
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Among women with childbearing
potential, ACE inhibitor, ARB, or statin
should only be used if there is reliable
contraception.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 4
4. ASA should not be routinely used for the primary
prevention of cardiovascular disease in people with
diabetes [Grade B, Level 2]
ASA may be used in the presence of additional cardiovascular risk factors [Grade D, Consensus]
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 5 and 6
5. Low-dose ASA therapy (81–325 mg) may be used
for secondary prevention in people with
established cardiovascular disease [Grade D, Consensus]
6. Clopidogrel (75 mg) may be used in people unable
to tolerate ASA [Grade D, Consensus]
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
CDA Clinical Practice Guidelines
www.guidelines.diabetes.ca – for professionals
1-800-BANTING (226-8464)
www.diabetes.ca – for patients